男友太凶猛1v1高h,大地资源在线资源免费观看 ,人妻少妇精品视频二区,极度sm残忍bdsm变态

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

EdiGene completes Series B financing round

By Liu Zhihua | chinadaily.com.cn | Updated: 2020-10-14 14:24
Share
Share - WeChat
A screenshot from EdiGene's official website. [Photo/edigene.com]

The Beijing-based EdiGene Inc, which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, announced on Tuesday the successful completion of a 450 million yuan ($67 million) round of Series B financing.

Founded in 2015, EdiGene has established four gene editing based platforms and is advancing its early stage programs into clinical development for patients with genetic diseases and cancer.

The four platforms are ex vivo genome editing platforms for hematopoietic stem cells and T cells, in vivo therapeutic platform based on RNA base editing and high-throughput genome-editing screening to discover novel targeted therapies.

In addition, EdiGene has launched a Good Manufacturing Practice facility in 2018 in Guangdong province.

3H Health Investment led the round, and other new investors included Sequoia Capital China, Alwin Capital and Kunlun Capital, along with continued support by previous investors, including IDG Capital, Lilly Asia Venture, Huagai Capital and Green Pine Capital Partners.

Proceeds from the financing will be used to advance the company’s pipeline into clinics and expand the team, the company said.

Wang Minchuan, partner of 3H Health Investment, said as one of the most disruptive biomedical technologies, gene editing is rapidly moving toward clinics globally, and EdiGene is leading the wave in China.

Wang said his firm looks forward to contributing its clinical, business and policy resources to further strengthen the company’s capabilities, and is confident EdiGene is well-positioned to be a leader in gene editing therapeutics.

Wei Dong, CEO of EdiGene, said the financing enables the company to further scale up and transform its pipeline into the clinical stage.

Wei Wensheng, scientific founder of EdiGene, said together with the investors, the company looks forward to translating cutting-edge gene editing technologies into innovative therapies, bringing hope and health to patients and their families.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 樟树市| 琼海市| 铜鼓县| 策勒县| 永善县| 甘孜县| 彝良县| 翼城县| 贡觉县| 新乐市| 高阳县| 景谷| 密山市| 铜山县| 大关县| 鄢陵县| 抚州市| 上林县| 云梦县| 大同市| 尉犁县| 延安市| 云浮市| 龙里县| 新昌县| 和顺县| 日喀则市| 金沙县| 英山县| 邻水| 遵义市| 汝阳县| 东乌珠穆沁旗| 潢川县| 平阴县| 清原| 吴旗县| 竹溪县| 类乌齐县| 通化市| 囊谦县|